Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Open accessThe DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index; 35 of the 93 sources its claims cite were checked for support.
Abstract
Glucagon-like peptide-1 (GLP-1) is an incretin hormone mainly secreted from intestinal L cells in response to nutrient ingestion. GLP-1 has beneficial effects for glucose homeostasis by stimulating insulin secretion from pancreatic beta-cells, delaying gastric emptying, decreasing plasma glucagon, reducing food intake, and stimulating glucose disposal. Therefore, GLP-1-based therapies such as GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase-4, which is a GLP-1 inactivating enzyme, have been developed for treatment of type 2 diabetes. In addition to glucose-lowering effects, emerging data suggests that GLP-1-based therapies also show anti-inflammatory effects in chronic inflammatory diseases including type 1 and 2 diabetes, atherosclerosis, neurodegenerative disorders, nonalcoholic steatohepatitis, diabetic nephropathy, asthma, and psoriasis. This review outlines the anti-inflammatory actions of GLP-1-based therapies on diseases associated with chronic inflammation in vivo and in vitro, and their molecular mechanisms of anti-inflammatory action.
Overview
CoChat Summary
## TL;DR
This review argues that GLP-1-based therapies have anti-inflammatory effects beyond glucose lowering, with evidence across diabetes, vascular disease, brain disorders, liver disease, nephropathy, and other inflammatory conditions. It summarizes in vitro, animal, and some human findings showing reductions in inflammatory cytokines, immune-cell infiltration, and related signaling pathways.
## Key findings
- In diabetes, GLP-1-based therapies reduced inflammatory mediators in islets and adipose tissue: liraglutide (100 nM) inhibited palmitate-induced TNF-α, IL-1β, and IL-6 in mouse islets; sitagliptin (100 mg/day) reduced plasma CRP, IL-6, IL-18, secreted phospholipase-A2, soluble ICAM-1, and E-selectin in type 2 diabetes patients, while the inflammatory score and HOMA index for insulin resistance were also significantly reduced.
- In vascular disease, liraglutide reduced adhesion molecules in endothelial cells and exendin-4 reduced atherosclerosis in mice; for example, exendin-4 (50 μg/kg/day) reduced atherosclerosis development and monocyte adhesion in APOE*3-Leiden.CETP mice, and sitagliptin reduced plaque macrophage infiltration and MMP-9 in ApoE−/− mice.
- In neurodegenerative disease models, liraglutide reduced activated microglia and inflammatory responses in Alzheimer’s disease models, and exendin-4 (10 μg/kg) decreased MPTP-induced microglial activation and TNF-α/IL-1β in Parkinson’s disease models.
- In other conditions, liraglutide improved asthma-related inflammation (including lower E-selectin, TNF-α, IL-4, IL-5, and IL-13) and exenatide improved sperm quality in diet-induced obese mice by suppressing testicular TNF-α, MCP-1, and F4/80.
## Methods
- Narrative review of published in vivo and in vitro studies on GLP-1, GLP-1 receptor agonists, and DPP-4 inhibitors across inflammatory diseases.
- Evidence base includes cell models, rodent and other animal models, and selected human studies (for example, patients with type 2 diabetes and nonalcoholic steatohepatitis).
- Main analysis was qualitative synthesis of anti-inflammatory effects and molecular mechanisms, organized by disease area and signaling pathways.
## Limitations
- The paper states that some reported benefits “need to be validated by clinical studies” for asthma, and that the safety of GLP-1-based therapy should be validated by “sufficient further studies” because rare cases of acute pancreatitis and neoplasms have been reported.
- Evident from the text: this is a review, so many conclusions are based on preclinical or small clinical studies rather than a single controlled synthesis or meta-analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
26 Valid · 0 Not valid · 23 Not checked · 23 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Inflammation can be a mediator of insulin resistance and beta-cell damage by high glucose, fatty acids, or adipokines released from adipose tissues [37–39].”
§ Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control > 2. Diabetes
What the sources say
- Partly supportedcites [37] matched to “Diabetes and beta cell function: from mechanisms to evaluation and clinical implications” (2013) sourceExperimental — accuracy not yet measured
The “Autoimmunity and inflammation” section (page not provided) says high glucose and free fatty acids induce islet inflammation that contributes to beta-cell impairment and apoptosis. The “Adipokines” section says some adipose-derived factors promote inflammation and beta-cell failure. The paper does not establish that inflammation mediates insulin resistance, so that part of the attributed claim is unsupported. (LLM, conf=0.84)
- Partly supportedcites [38] matched to “β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment” (2014) sourceExperimental — accuracy not yet measured
The “Metabolic and Oxidative Stress” passage links glucotoxicity and lipotoxicity to β-cell damage. The “Inflammation” passage describes local islet inflammation in type 2 diabetes and says anti-inflammatory treatment can preserve some β-cell functional mass. Our copy does not establish that inflammation mediates insulin resistance or damage caused by adipose-derived adipokines, and it leaves the origin of islet inflammation unresolved. The indexed passages provide no page numbers. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [39] matched to “Mechanisms of Pancreatic β-Cell Death in Type 1 and Type 2 Diabetes” (2005) source
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Therefore, suppression of CXCL10 production by exendin-4 could reduce islet inflammation by decreasing cytotoxic T lymphocyte recruitment into the islets in autoimmune type 1 diabetes [48].”
§ Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control > 2. Diabetes
What the sources say
- Supportedcites [48] matched to “Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients” (2010) source
The paper's own Results ("Suppression of IFN-γ-induced CXCR3-binding chemokines by exendin-4 and cyclic AMP in human islets") show exendin-4 suppressing CXCL10 mRNA (~30% with rolipram, modest but significant with exendin-4 alone) and protein (38%), with reduced secretion into the medium, and the Introduction states that "CXCL10 plays an important role in trafficking effector T cells to islets during insulitis in type 1 diabetes" and that "suppression of CXCL10 production in islets could be an important therapeutic approach to reducing insulitis in type 1 diabetes." The citing sentence's hedged inference ("could reduce islet inflammation by decreasing ... T lymphocyte recruitment") reproduces that same reasoning, with "cytotoxic T lymphocyte" standing in for the source's CXCR3-bearing effector/activated T cells and NK cells. The source is in vitro human islets and MIN6 cells, so the type 1 diabetes benefit remains a stated possibility in both documents, not a demonstrated outcome. (LLM, conf=0.85)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Expression of the GLP-1 receptor is widely detected in various cells and organs including the kidney, lung, heart, hypothalamus, endothelial cells, neurons, astrocytes, and microglia as well as pancreatic beta-cells [12–17]”
§ Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control > 1. Introduction
What the sources say
- Partly supportedcites [12] matched to “Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4” (2010) sourceExperimental — accuracy not yet measured
The Results section (page unavailable) reports GLP-1 receptor expression in lung, pancreatic β-cells, and endothelial cells; the introductory text also refers broadly to neural cells. The paper does not establish receptor expression in the kidney, heart, hypothalamus, astrocytes, or microglia, nor does it identify neurons specifically. Its discussion of GLP-1 effects on the heart is not evidence of receptor expression there. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [13] matched to “Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.” (1992) source
- Not checked — no full text of the sourcecites [14] matched to “The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential” (2014) source
- Not checked — no full text of the sourcecites [15] matched to “Pulmonary GLP-1 Receptor Increases at Birth and Exogenous GLP-1 Receptor Agonists Augmented Surfactant-Protein Levels in Litters From Normal and Nitrofen-Treated Pregnant Rats” (2013) source
- Not checked — no full text of the sourcecites [16] matched to “Distribution of GLP‐1 Binding Sites in the Rat Brain: Evidence that Exendin‐4 is a Ligand of Brain GLP‐1 Binding Sites” (1995) source
- Not checked — no full text of the sourcecites [17] matched to “Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes” (2006) source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Thus, GLP-1 therapy may be beneficial for the treatment of chronic inflammatory diseases including nonalcoholic steatohepatitis, atherosclerosis, neurodegenerative disorders, diabetic nephropathy, asthma, and psoriasis [14, 26–32].”
§ Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [14] matched to “The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential” (2014) source
- Partly supportedcites [26] matched to “Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe −/− mice” (2012) sourceExperimental — accuracy not yet measured
Vittone et al. (2012) supports only the atherosclerosis element of the list: the Discussion (p. 6) states that sitagliptin 'decreases plaque macrophage content and stabilises arteriosclerotic lesions in Apoe -/- mice, while GLP-1 directly inhibits monocyte migration and macrophage MMP-9 production in vitro', and the same passage notes broadly that 'there is evidence of anti-inflammatory effects of GLP-1 in different tissues'. Our copy makes no claim that GLP-1 therapy is beneficial in nonalcoholic steatohepatitis, diabetic nephropathy or asthma (searched: those terms plus 'chronic inflammatory diseases'); neurodegenerative and psoriatic disease appear only as titles of cited works (refs 25 and 26, References p. 9), not as conditions this paper shows GLP-1 treats. The remaining diseases in the citing list must rest on the other citations in the cluster [14, 26–31]. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [27] matched to “The role of glial cells in Parkinsonʼs disease” (2001) source
- Not checked — no full text of the sourcecites [28] matched to “Glucagon‐like peptide‐1 preserves non‐alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress‐associated pathway” (2016) source
- Not checked — no full text of the sourcecites [29] matched to “Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1” (2011) source
- Not checked — no full text of the sourcecites [30] matched to “Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-κB in mice” (2014) source
- Partly supportedcites [31] matched to “Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis” (2011) sourceExperimental — accuracy not yet measured
The Conclusions/interpretation and Discussion (pages not provided) suggest therapeutic potential for GLP-1 in inflammatory conditions such as psoriasis, based on improvement observed in patients. The Discussion also mentions cardiovascular and neuroprotective effects, but the paper does not support the full list of proposed treatments, particularly nonalcoholic steatohepatitis, diabetic nephropathy, and asthma. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [32] matched to “Exendin-4 and GLP-1 decreases induced expression of ICAM-1, VCAM-1 and RAGE in human retinal pigment epithelial cells” (2013) source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“emerging data suggest that GLP-1-based therapies also showed anti-inflammatory effects on the liver, vascular system including aorta and vein endothelial cells, brain, kidney, lung, testis, and skin by reducing the production of inflammatory cytokines and infiltration of immune cells in the tissues [17, 21–25].”
§ Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [17] matched to “Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes” (2006) source
- Partly supportedcites [21] matched to “Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation” (2014) sourceExperimental — accuracy not yet measured
The GLP-1RAs AND INFLAMMATION section reports anti-inflammatory effects in endothelial cells and reduced inflammatory-cytokine release; the IL-6 and chemokines sections report reductions in the liver, brain, and kidney. The monocytes/macrophages section reports reduced macrophage infiltration in adipose tissue, not across the listed organs. The cited passages do not establish anti-inflammatory effects in the aorta, lung, testis, or skin. Page numbers were not available in our copy. (LLM, conf=0.88)
- Could not verifycites [22] matched to “Anti-proliferative effect of pro-inflammatory cytokines in cultured β cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide -1” (2008) sourceExperimental — accuracy not yet measured
Our copy of Blandino-Rosano et al. (2008) is confined to rat pancreatic islet/β-cell culture: the Abstract and the results section 'GLP-1 has a protective role against anti-proliferative effects of cytokines' show GLP-1 reversing IL-1β/IFN-γ/TNF-α-induced ERK1/2 inactivation and restoring β-cell proliferation, and the Discussion frames this as possible use in early-stage DM1. No passage addresses anti-inflammatory actions of GLP-1-based therapies in liver, aorta/vein endothelium, brain, kidney, lung, testis or skin, nor reduced cytokine production or immune-cell infiltration in those tissues (searched: extrapancreatic tissues/endothelial/kidney/anti-inflammatory in vivo; inflammatory cytokine production and immune infiltration). Since our copy neither states nor contradicts the tissue-level claim, it cannot be verified from this source. (LLM, conf=0.70)
- Partly supportedcites [23] matched to “A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules” (2009) sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [24] matched to “The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain” (2013) source
- Partly supportedcites [25] matched to “Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals” (2014) sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
47 more claims · 13 with their cited sources checked
Create a free account to see all 72 claims and to verify the 6 references still open.
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1RAs have effects on systemic inflammation such as reduction in high-sensitivity C-reactive protein (hs-CRP) that are not mediated by weight loss or glycemic control [15, 27, 28].”
From evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There is increasing evidence that GLP-1RAs act as modulators of atherosclerosis, 76 and their anti-inflammatory and antioxidant properties may contribute to this, as supported by laboratory studies. 77,78”
The cited source says what the claim attributes to it.
In the citing paper
“Experimental and translational data support anti‐inflammatory and antioxidant actions of GLP‐1RAs beyond glycemic control [5].”
The cited source says what the claim attributes to it.
In the citing paper
“These benefits suggest important non‐glycemic effects, including modulation of inflammatory and vascular pathways [5].”
The cited source says what the claim attributes to it.
In the citing paper
“GLP‐1 receptor signalling may inhibit pro‐inflammatory transcriptional pathways, attenuate oxidative stress, improve endothelial function and modulate immune cell activation [5, 10].”
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Nonalcoholic steatohepatitis [61, 93, 96]”
Cited work 10.1007/s00125-010-1831-8 · retracted 2011-12-15 · notice 10.1007/s00125-011-2394-z · this paper published 2016
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183 · cited 3×
“Nonalcoholic steatohepatitis [61, 93, 96]”
BackgroundRetractedRole of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Kanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“GLP-1 has many beneficial effects on the control of blood glucose levels including stimulation of insulin secretion and inhibition of glucagon secretion, expansion of the beta-cell mass by stimulating beta-cell proliferation and differentiation and inhibiting beta-cell apoptosis, delay of gastric emptying, and reducti…”
BackgroundMicroglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism
Block, M. L., & Hong, J.-S. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.06.004 · Cited by 1,557
CCR2 modulates inflammatory and metabolic effects of high-fat feeding
Weisberg, S. P., Hunter, D., Huber, R., Lemieux, J., Slaymaker, S., Vaddi, K., Charo, I., Leibel, R. L., & Jr., A. W. F. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24335 · Cited by 1,497
Mechanisms of Pancreatic β-Cell Death in Type 1 and Type 2 Diabetes
Cnop, M., Welsh, N., Jonas, J.-C., Jörns, A., Lenzen, S., & Eizirik, D. L. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s97 · Cited by 1,491
CCR2 modulates inflammatory and metabolic effects of high-fat feeding
Weisberg, S. P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24335c1 · Cited by 1,425
Normalization of obesity-associated insulin resistance through immunotherapy
Winer, S., Chan, Y., Paltser, G., Truong, D., Tsui, H., Bahrami, J., Dorfman, R., Wang, Y., Zielenski, J., Mastronardi, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2001 · Cited by 1,370
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Cited by
Items 201–300 of 501
Anti-inflammatory effects of GLP-1 in patients with COVID-19
Sazgarnejad, S., Yazdanpanah, N., & Rezaei, N. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1964955 · Cited by 21
Expanding the drug discovery space with predicted metabolite–target interactions
Nuzzo, A., Saha, S., Berg, E. L., Jayawickreme, C. K., Tocker, J. E., & Brown, J. R. (2021) · Communications Biology · doi:10.1038/s42003-021-01822-x · Cited by 23
Interplay Between the Immune and Endocrine Systems in the Lung: Implications for TB Susceptibility
Webber, T., Ronacher, K., Conradie-Smit, M., & Kleynhans, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.829355 · Cited by 27
Wongkrasant, P., Pongkorpsakol, P., Chitwattananont, S., Satianrapapong, W., Tuangkijkul, N., & Muanprasat, C. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.03.001 · Cited by 25
Омаровна, К. И., Zhernakova, Y. V., & Blinova, N. V. (2023) · Systemic Hypertension · doi:10.38109/2075-082x-2022-4-37-44 · Cited by 24
Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?
Janić, M., Škrgat, S., Harlander, M., Lunder, M., Janež, A., Stoian, A. P., El‐Tanani, M., Maggio, V., & Rizzo, M. (2024) · Medicina · doi:10.3390/medicina60122030 · Cited by 33
“On the other hand, the production of anti-inflammatory cytokines, such as IL-10, increases in addition to mannose receptor-1 (MRC-1) and the release of arginine-1 (Arg-1), prostaglandin E2 (PGE2), and cyclooxygenase 2 (COX2) [18–20].”
Bułdak, Ł., Machnik, G., Skudrzyk, E., Bołdys, A., & Okopień, B. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7245 · Cited by 21
ACE2 and SARS-CoV-2 Infection: Might GLP-1 Receptor Agonists Play a Role?
Monda, V. M., Porcellati, F., Strollo, F., & Gentile, S. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00898-8 · Cited by 21
“Indeed, multiple preclinical studies performed in mice and rats with experimental induced lung injury demonstrated that GLP-1 RAs attenuate pulmonary inflammation, through inhibitory activity on cytokine release [10, 11], as a result of their interference with nuclear factor-kB signaling pathways [12].”
BackgroundLin, C.-P., Huang, P., Chen, C., Wu, M., Chen, J.-S., Chen, J., & Lin, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-97361-w · Cited by 23
Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists
Jensen, E., Israelsen, M. E., & Krag, A. A. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000561 · Cited by 25
Saad, Z. A., Khodeer, D. M., Zaitone, S. A., Ahmed, A. A. M., & Moustafa, Y. M. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117725 · Cited by 23
Liao, S., Linderholm, A., Showalter, M. R., Chen, C., Fiehn, O., & Kenyon, N. J. (2021) · Obesity Science & Practice · doi:10.1002/osp4.500 · Cited by 22
“Nitric oxide can directly inhibit TNF‐α secretion(5) whereas GLP‐1 indirectly inhibits TNF‐α secretion through increasing nitric oxide levels and inhibition of the NF‐kB pathway.(31) Arginine supplementation inhibits TNF‐α synthesis through the induction of arginase activity,(32) supporting our hypothesis.”
BackgroundO’Brien, R., & O’Malley, D. (2019) · Neurogastroenterology & Motility · doi:10.1111/nmo.13738 · Cited by 24
Chitosan nanovectors for siRNA delivery: New horizons for nonviral gene therapy
Rahimi, M., Kariminezhad, Z., Rondon, E.-P., Fahmi, H., Fernandes, J., & Benderdour, M. (2025) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2025.123581 · Cited by 23
DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis
Padron, S., Rogers, E., Beckler, M. D., & Kesselman, M. M. (2019) · BMJ Case Reports · doi:10.1136/bcr-2018-228981 · Cited by 21
van Eenige, R., Ying, Z., Tramper, N., Wiebing, V., Siraj, Z., de Boer, J. F., Lambooij, J. M., Guigas, B., Qu, H., Coşkun, T., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.016 · Cited by 20
GLP-1/Sigma/RAGE receptors: An evolving picture of Alzheimer's disease pathology and treatment
Neha, N., Wali, Z., Pinky, P., Hattiwale, S. H., Jamal, A., & Parvez, S. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102134 · Cited by 20
Wang, Y., Shi, Y., Peng, X., Li, T., Liang, C., Wang, W., Zhou, M., Yang, J., Cheng, J., Zhang, Z., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202303958 · Cited by 22
Mehta, K., Behl, T., Kumar, A., Uddin, M. S., Zengin, G., & Arora, S. (2020) · Current Protein and Peptide Science · doi:10.2174/1389203721999201208195901 · Cited by 21
Lymperopoulos, A., Borges, J. I., & Stoicovy, R. A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060693 · Cited by 23
GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity
Alharbi, A. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00038-y · Cited by 34
“GLP-1RAs disrupt this inflammatory cascade by diminishing adipose tissue macrophage infiltration, enhancing insulin sensitivity via reduced inflammatory signaling, and safeguarding pancreatic β-cells from inflammatory harm (Pang et al. 2022; Lee and Jun 2016).”
Pinto, S., Viegas, J. S. R., Cristelo, C., Pacheco, C., Barros, S., Buckley, S. T., Garousi, J., Gräslund, T., Santos, H. A., & Sarmento, B. F. C. C. (2024) · ACS Nano · doi:10.1021/acsnano.4c11172 · Cited by 22
Bai, Y., Lian, P., Li, J., Zhang, Z., & Jian, Q. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104645 · Cited by 21
Taguchi, K., Bessho, N., Kaneko, N., Okudaira, K., Matsumoto, T., & Kobayashi, T. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172776 · Cited by 20
Masson, W., Lobo, M., Barbagelata, L., Lavalle-Cobo, A., & Molinero, G. (2021) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2021.06.001 · Cited by 17
Zhu, H., Liu, Z.-P., Yang, W., Dong, D.-W., Zhao, Y. H., Yang, B. Y., Huang, L., Zhang, Y., & Xu, A.-D. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00962 · Cited by 18
“Recently, many studies have shown that GLP-1R agonists have the effect on anti-inflammatory (Lee and Jun, 2016).”
BackgroundImpact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review
Haran, K., Johnson, C., Smith, P. L., Venable, Z., Kranyak, A. C., Bhutani, T., Jeon, C., & Liao, W. J. (2024) · Psoriasis Targets and Therapy · doi:10.2147/ptt.s485061 · Cited by 34
Becker, E. J., Faiz, A., van den Berge, M., Timens, W., Hiemstra, P. S., Clark, K. P., Liu, G., Xiao, X., Alekseyev, Y. O., O’Connor, G. T., et al. (2021) · Thorax · doi:10.1136/thoraxjnl-2019-214476 · Cited by 23
Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review
Popovic, D. S., Παπάνας, Ν., Stoian, A. P., Rizvi, A. A., Janež, A., & Rizzo, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01170-3 · Cited by 18
“Additionally, DPP4 degrades endogenous GLP1, which also harbours anti-inflammatory properties [28, 29].”
BackgroundXie, Z., Yang, Z., Tian, D., & Chen, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1618079 · Cited by 22
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Zhou, Q., Li, G., Hang, K., Li, J., Yang, D., & Wang, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061324-011832 · Cited by 16
Mahdy, R. N. E., Nader, M. A., Helal, M. G., Abu-Risha, S. E.-S., & Abdelmageed, M. E. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03631-5 · Cited by 20
“…which is secreted by intestinal endocrine L cells, regulate metabolic processes (Yaribeygi et al. 2021) as GLP-1 is implicated in pathophysiological processes that can lead to inflammation, cardiovascular, and nervous system disorders (Lee and Jun 2016, Rakipovski et al. 2018, Li et al. 2021).”
Central administration of coagonist of GLP-1 and glucagon receptors improves dyslipidemia
PATEL, V. G., Joharapurkar, A. A., Kshirsagar, S. G., Sutariya, B., Patel, M. S., Patel, H., Pandey, D., Patel, D. N., Bahekar, R. H., & Jain, M. R. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.12.068 · Cited by 18
Davis, H., Briscoe, V. J., Dumbadze, S., & Davis, S. N. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1592156 · Cited by 16
Yonekawa, A., & Shimono, N. (2022) · Biology · doi:10.3390/biology11030400 · Cited by 22
Exenatide mitigates inflammation and hypoxia along with improved angiogenesis in obese fat tissue
Xian, Y., Chen, Z., Deng, H., Cai, M., Liang, H., Xu, W., Weng, J., & Xu, F. L. (2019) · Journal of Endocrinology · doi:10.1530/joe-18-0639 · Cited by 18
“Accumulating data from both clinical and animal studies has shown potential anti-inflammatory effect of GLP-1 receptor agonist on the cellular and molecular level (Lee & Jun 2016).”
BackgroundSevere Insulin Resistance Syndromes: Clinical Spectrum and Management
Pliszka, M., & Szablewski, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125669 · Cited by 23
Lin, F., Shih, C.-M., Huang, C., Tsai, Y.-T., Loh, S., Li, C., Lin, C.-Y., Lin, Y., & Tsai, C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07013-w · Cited by 16
Wahba, N. S., Ghareib, S. A., Abdel-Ghany, R. H., Abdel-Aal, M., & Alsemeh, A. E. (2020) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2020-0435 · Cited by 16
RetractedDapagliflozin protects neural and vascular dysfunction of the retina in diabetes
Luo, Q., Leley, S. P., Bello, E., Dhami, H., Mathew, D., & Bhatwadekar, A. D. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-002801 · Cited by 16
Stoicovy, R. A., Cora, N., Perez, A., Nagliya, D., Calvo, G. D., Lopez, T. B., Weinstein, E., Borges, J. I., Maning, J., & Lymperopoulos, A. (2024) · Inflammation Research · doi:10.1007/s00011-024-01950-0 · Cited by 19
Srivastava, S., Pandey, H. K., Singh, S. K., & Tripathi, Y. B. (2019) · BioScience Trends · doi:10.5582/bst.2019.01181 · Cited by 15
Catrinoiu, D. (2020) · FARMACIA · doi:10.31925/farmacia.2020.3.1 · Cited by 17
“Animal studies showed a GLP-1 agonists upregulation effect upon ACE2 expressed at alveolar microlevel and a negative effect on inflammation through the inhibition of citokine release, mechanisms that may be of benefit during COVID-19 infection [38].”
BackgroundCéspedes, N., Donnelly, E. L., Garrison, S. M., Haapanen, L. A. D., de Water, J. V., & Luckhart, S. (2020) · Infection and Immunity · doi:10.1128/iai.00427-20 · Cited by 16
Angiotensin-Converting Enzyme 2 Expression and Severity of SARS-CoV-2 Infection
Alabsi, S. M., Dhole, A., Hozayen, S. M., & Chapman, S. A. (2023) · Microorganisms · doi:10.3390/microorganisms11030612 · Cited by 18
Lee, J. H. (2021) · Medical Hypotheses · doi:10.1016/j.mehy.2021.110739 · Cited by 15
Scheen, A. J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101612 · Cited by 16
Lucente, D., Bellino, S., & Salvia, A. L. (2025) · Genes · doi:10.3390/genes16111352 · Cited by 18
“Careful assessment of potential adverse events, including pancreatic, thyroidal, and cardiovascular effects, as well as their interactions with standard oncologic therapies, will be essential to ensure that any therapeutic benefit is not offset by toxicity or disease exacerbation over time [38].”
Tocilizumab increases citrullinated histone 3 in non-ST segment elevation myocardial infarction
Helseth, R., Kleveland, O., Ueland, T., Wiseth, R., Damås, J. K., Broch, K., Michelsen, A. E., Bendz, B., Gullestad, L. L., Aukrust, P., et al. (2021) · Open Heart · doi:10.1136/openhrt-2020-001492 · Cited by 14
GLP-1 receptor agonists as promising disease-modifying agents in WFS1 spectrum disorder
Panfili, E., Frontino, G., & Pallotta, M. T. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1171091 · Cited by 16
“Hence, thanks to their pleiotropic properties, GLP-1RAs are emerging as suitable for the treatment of diseases associated with chronic inflammation, including type 1 and 2 diabetes, neurodegenerative diseases, atherosclerosis, diabetic nephropathy, asthma, psoriasis, nonalcoholic steatohepatitis (58, 59).”
BackgroundHardoňová, M., Šiarnik, P., Siváková, M., Sucha, B., Penesová, A., Rádiková, Ž., Havranová, A., Imrich, R., Vlček, M., Žitňanová, I., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311162 · Cited by 16
“As a result of reduced ROS production, GLP-1as also have a protective effect against oxidative damage [26], which may reduce the risk of subsequent microvascular injury [27].”
BackgroundChang, Y., Dong, M., Wang, Y., Yu, H., Sun, C., Jiang, X., Chen, W., Wang, X., Xu, N., Liu, W., et al. (2019) · Stem Cells International · doi:10.1155/2019/4961865 · Cited by 14
Leon, R. M., Borner, T., Stein, L. M., Urrutia, N. A., Jonghe, B. C. D., Schmidt, H. D., & Hayes, M. R. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108477 · Cited by 13
“In addition to glucoregulation and satiation (Barrera et al, 2011; Cabou et al, 2008; Müller et al, 2019), the GLP-1 system plays a role in the behavioral and physiological response to stress (Ghosal et al, 2013; Herman, 2018; Holt et al, 2016), nausea/emesis (De Jonghe et al, 2016; Kanoski et al, 2012; Kinzig et al,…”
BackgroundEkhzaimy, A. A., Masood, A., Benabdelkamel, H., Elhassan, T., Musambil, M., & Alfadda, A. A. (2022) · Diabetes and Vascular Disease Research · doi:10.1177/14791641221094322 · Cited by 16
Izaguirre, M., Gómez‐Ambrosi, J., Rodríguez, A., Ramírez, B., Becerril, S., Valentí, V., Moncada, R., Unamuno, X., Silva, C., de la Higuera, M., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040479 · Cited by 14
“In addition to the well-documented glucoregulatory actions of GLP-1, its role as an anti-inflammatory factor on different models has been reported [15,16].”
BackgroundDownregulation of IL-18 Expression in the Gut by Metformin-induced Gut Microbiota Modulation
Lee, H., Kim, J., An, J., Lee, S., Choi, D., Kong, H., Song, Y., Park, I.-H., Lee, C., & Kim, K. (2019) · Immune Network · doi:10.4110/in.2019.19.e28 · Cited by 16
Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact
Lee, A. A., Khotina, V. A., Kashirskikh, D. A., Voronko, O. E., Gasanov, V. A. O., & Vasiliev, A. V. (2025) · Medical Sciences · doi:10.3390/medsci13040269 · Cited by 26
Zhan, K., Weng, L., Li, Q., Wang, L., Lin, H., Fang, X., Jia, H., & Ma, X. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280221133577 · Cited by 14
Foresta, A., Fernandez, M. L. O., Macaluso, G., Roncaglioni, M. C., Tettamanti, M., Fortino, I., Leoni, O., Genovese, S., & Baviera, M. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.02.007 · Cited by 13
Nabi, T., Riyed, T. H., & Ornob, A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0303954 · Cited by 16
Exendin-4 improves behaviorial deficits via GLP-1/GLP-1R signaling following partial hepatectomy
Zhou, Y., Li, Z., Cao, X., Ma, H., White, P. F., Xu, X., Jiang, Y., Sun, X.-J., & Cui, Y. (2018) · Brain Research · doi:10.1016/j.brainres.2018.11.007 · Cited by 14
Lundgren, J. R., Færch, K., Witte, D. R., Jonsson, A. E., Pedersen, O. B., Hansen, T. F., Lauritzen, T., Holst, J. J., Vistisen, D., Jørgensen, M. E., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0937-7 · Cited by 14
Zhu, C., Tao, H., Rong, S., Xiao, L., Li, X., Jiang, S., Guo, B., Wang, L., Ding, J., Gao, C., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.694476 · Cited by 16
Ebbesen, M., Kissow, H., Hartmann, B., Grell, K., Gørløv, J. S., Kielsen, K., Holst, J. J., & Müller, K. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.01.036 · Cited by 16
Lee, Y.-J., Fang, Y., Chen, M., Liou, H., Li, T.-H., & Tsai, M. (2025) · Journal of Autoimmunity · doi:10.1016/j.jaut.2025.103453 · Cited by 20
Self-citationWu, J., Cheng, A. S., Weimbs, T., Harris, P. C., Zhou, J. X., & Li, X. (2025) · The FASEB Journal · doi:10.1096/fj.202501605r · Cited by 15
“In addition, how Semaglutide induces apoptosis, a mechanism previously linked to GLP- 1RA-mediated elimination of damaged cells [64], also needs to be elucidated.”
The protective role of GLP-1 in neuro-ophthalmology
Sheth, S., Patel, A., Foreman, M. A., Mumtaz, M., Reddy, A., Sharaf, R., Sheth, S., & Lucke-Wold, B. P. (2023) · Exploration of Drug Science · doi:10.37349/eds.2023.00015 · Cited by 15
“Beyond its well-established role in glucose control in diabetes mellitus, GLP-1 has increasingly become the target of anti-inflammatory therapies for the management of conditions such as atherosclerosis, nonalcoholic steatohepatitis, nephropathy secondary to diabetes, and neurodegenerative disorders [44].”
BackgroundSemaglutide and heart failure: Updated meta-analysis.
Barbagelata, L., Masson, W. M., Lobo, M., & Bluro, I. M. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102721 · Cited by 13
Immune System Effects of Insulin-Like Peptide 5 in a Mouse Model
Vahkal, B., Yegorov, S., Onyilagha, C., Donner, J., Reddick, D., Shrivastav, A., Uzonna, J. E., & Good, S. V. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.610672 · Cited by 13
Bullous Pemphigoid Triggered by Liraglutide
Collins, M.-K. (2021) · Cutis · doi:10.12788/cutis.0262 · Cited by 12
Shang, K., Xia, Z.-J., Ye, X., Li, Z., & Gong, C. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-057698 · Cited by 11
Garczorz, W., Gallego-Colón, E., Kosowska, A., Siemianowicz, K., Kłych‐Ratuszny, A., Woźniak, M., Aghdam, M. R. F., Francuz, T., & Dorecka, M. (2018) · Pharmacological Reports · doi:10.1016/j.pharep.2018.10.003 · Cited by 11
The impact of obesity on cardiovascular disease risk factor
Kumar, A. (2018) · Asian Journal of Medical Sciences · doi:10.3126/ajms.v10i1.21294 · Cited by 21
Barón, N. B., Kankaanranta, H., Hedman, L., Andersson, M., Stridsman, C., Lindberg, A., Rönmark, E., & Bäckman, H. (2022) · ERJ Open Research · doi:10.1183/23120541.00110-2022 · Cited by 16
Chiang, C., Chang, Y., Yu, C.-C., See, X. Y., Wang, T. H., Xanthavanij, N., Song, J., Lo, S., Chiang, C.-H., Lake, L. L., et al. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.06.020 · Cited by 15
Mahgoub, S., Fatahala, S. S., Sayed, A. I., Atya, H. B., Shehry, M. F. E., Afifi, H., Awad, S. M., El-Hameed, R. H. A., & Taha, H. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106092 · Cited by 14
“Studies revealed that DPP-4 inhibition may alienate SARS–CoV-2 virulence and the subsequent multiorgan damage via several mechanisms that include decreasing the overproduction of cytokines [56,60]; reducing the activity of macrophages [61]; inducing direct pulmonary anti-inflammatory effects [62,63]; and finally augme…”
Stenlid, R., Cerenius, S. Y., Quan, W., Aydın, B. K., Manell, H., Chowdhury, A. I., Kristinsson, H., Ciba, I., Gjessing, E. S., Mörwald, K., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1293093 · Cited by 11
Fan, W., Zhang, Q., Wang, C., Sun, J., Zhang, J., & Yin, Y. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114390 · Cited by 17
Semaglutide in MASLD Patients: Improved Survival and Liver Outcomes
Suki, M., Amer, J., Milgrom, Y., Massarwa, M., Hazou, W., Tiram, Y., Perzon, O., Sharif, Y., Sackran, J., Alon, R., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18071075 · Cited by 12
“…suggests multiple complementary mechanisms through which the drug may exert its hepatoprotective effects, including reducing inflammation (reflected in clinical presentations) [20], improving liver function (reflected in laboratory parameters), and decreasing the need for ALD-specific medications.”
InfluentialMarzoog, B. A., & Vlasova, T. I. (2022) · Obesity and metabolism · doi:10.14341/omet12778 · Cited by 14
Rajagopal, S., Alruwaili, F., Mavratsas, V., Serna, M. K., Murthy, V. L., & Raji, M. (2023) · Cureus · doi:10.7759/cureus.51352 · Cited by 11
Shen, W.-R., Kitaura, H., Qi, J., Ogawa, S., Ohori, F., Noguchi, T., Marahleh, A., Nara, Y., Pramusita, A., & Mizoguchi, I. (2020) · The Angle Orthodontist · doi:10.2319/021320-103.1 · Cited by 19
“Exendin-4 reportedly blocks TNF-a expression by inhibiting intracellular NF-jB signaling.(7) Exendin-4 also directs macrophage polarization toward the M2 phenotype; therefore, expression levels of M1 macrophage cytokines (eg, TNF-a) are reduced.”
BackgroundSu, Y., Hsieh, P.-C., Lai, E. C., Lin, Y.-C., & Lin, Y.-C. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101545 · Cited by 13
Alnaser, R. I., Alassaf, F. A., & Abed, M. N. (2024) · Journal of Bone Metabolism · doi:10.11005/jbm.24.739 · Cited by 14
“[ 62] These mechanisms work to increase insulin secretion,[63] decrease oxidative stress,[63] decrease inflammatory response,[64] increase expression and localization of GLUT-4 in insulin-sensitive tissue,[65] improve the plasma lipid profile; which regulates lipid metabolism,[66] enhance the…”
Suryaningtyas, I. T., Jung, W., Lee, S., & Je, J. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114844 · Cited by 12
Stabilizing Cellular Barriers: Raising the Shields Against COVID-19
Hanchard, J., Capó-Vélez, C. M., Deusch, K., Lidington, D., & Bolz, S.-S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.583006 · Cited by 10
“In addition to its functions as a metabolic hormone, GLP-1 possesses significant antiinflammatory effects that are independent of glucose homeostasis (118).”
BackgroundPsoriasis and neurodegenerative diseases—a review
Nowowiejska, J., Baran, A. M., & Flisiak, I. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.917751 · Cited by 10
Pershina, О. V., Pakhomova, A. V., Widera, D., Ermakova, N. N., Epanchintsev, A. A., Pan, E. S., Krupin, V. A., Ваизова, О. Е., Putrova, О. D., Sandrikina, L. A., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215414 · Cited by 11
“It is well known that GLP-1 stimulates insulin production by islet β-cells, counteracts insulin resistance, improves peripheral glucose tolerance, and has anti-inflammatory properties [34,35].”
BackgroundShah, F. A., Singamsetty, S., Guo, L., Chuan, B. W., McDonald, S., Cooper, B. A., O’Donnell, B. J., Stefanovski, D., Wice, B. M., Zhang, Y., et al. (2017) · Translational research · doi:10.1016/j.trsl.2017.11.001 · Cited by 12
Anti-inflammatory properties of antidiabetic agents
Xourgia, E., Tzouganatou, E.-M., Papazafiropoulou, A. K., & Melidonis, A. I. (2019) · World Journal of Meta-Analysis · doi:10.13105/wjma.v7.i4.129 · Cited by 11
Khine, H. E. E., Mangmool, S., & Parichatikanond, W. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178233 · Cited by 9
Hunger & satiety signals: another key mechanism involved in the NAFLD pathway
López-Méndez, I., Maldonado-Rojas, A. D. C., Uribe, M., & Juárez-Hernández, E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1213372 · Cited by 10
Zaky, D. A., Abdallah, D. M., & El‐Abhar, H. S. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176191 · Cited by 9
Klein, J. A., St‐Pierre, J., Choi, D., Lopez, J., & Rubin, D. T. (2024) · ACG Case Reports Journal · doi:10.14309/crj.0000000000001544 · Cited by 11
Wang, J., Lee, C., Ko, W., Wu, L., & Chang, C. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112324 · Cited by 11
Patton, L., Reverdito, V., Bellucci, A., Bortolon, M., Macrelli, A., & Ricolfi, L. (2025) · Clinics and Practice · doi:10.3390/clinpract15070128 · Cited by 15
“Other studies have shown the effect of exenatide on reducing inflammation and hypoxia in adipose tissue by improving angiogenesis and microcirculation [34].”
Kishimori, T., Kato, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Iwasaki, Y., Matsumoto, T., Yagi, T., & Okada, M. (2025) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaf065 · Cited by 8
Zhang, J., Sanan, S., Csanalosi, M., Zheng, C., & Pfeiffer, A. F. H. (2025) · Endocrinology · doi:10.1210/endocr/bqaf130 · Cited by 15
Krzystek‐Korpacka, M., Fleszar, M. G., Fortuna, P., Gostomska‐Pampuch, K., Lewandowski, Ł., Piasecki, T., Kosyk, B., Szeląg, A., & Trocha, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313155 · Cited by 11
“However, the drug effect on the liver profile of eicosanoids during IR has not been investigated, although sitagliptin has been demonstrated to reduce both PLA2 and COX2 concentration in various clinical and experimental settings [34,35].”
BackgroundResultTseng, Y., Chen, M., Lai, R., Oieni, F., Smyth, G., Anoopkumar‐Dukie, S., John, J. A. S., & Ekberg, J. A. K. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111819 · Cited by 9
Metadata
- Authors
- Lee, Y.-S., & Jun, H.-S.
- Affiliations
- Gachon University (KR)
- Corresponding author
- Jun, Hee-Sook
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2016
- Volume
- 2016
- Pages
- 1-11
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- PMC
- PMC4823510
- OpenAlex
- W2306319461
- Cited by
- 530
- References
- 116
- Citations by year
- 2026: 68 · 2025: 83 · 2024: 56 · 2023: 52 · 2022: 60 · 2021: 72 · 2020: 53 · 2019: 47 · 2018: 21 · 2017: 15 · 2016: 3
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Mediators of Inflammation (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation of Korea (2015R1D1A1A01060232)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- glucagon-like peptide-1, GLP-1 receptor agonists, DPP-4 inhibitors, anti-inflammatory activity, chronic inflammation, type 2 diabetes, type 1 diabetes, atherosclerosis, neurodegenerative diseases, nonalcoholic steatohepatitis, diabetic nephropathy, asthma, psoriasis, glucose homeostasis, molecular mechanisms of inflammation
- MeSH terms
- Animals, Anti-Inflammatory Agents, Blood Glucose, Diabetes Mellitus, Type 2, Humans, Inflammation, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.